ATE360061T1 - Replikationsmangelhafte mutanten von herpesvirus - Google Patents

Replikationsmangelhafte mutanten von herpesvirus

Info

Publication number
ATE360061T1
ATE360061T1 AT95907356T AT95907356T ATE360061T1 AT E360061 T1 ATE360061 T1 AT E360061T1 AT 95907356 T AT95907356 T AT 95907356T AT 95907356 T AT95907356 T AT 95907356T AT E360061 T1 ATE360061 T1 AT E360061T1
Authority
AT
Austria
Prior art keywords
replication
herpesvirus
herpes virus
mutated
mammal
Prior art date
Application number
AT95907356T
Other languages
English (en)
Inventor
David Knipe
Robert Finberg
George Siber
Original Assignee
Harvard College
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26874996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE360061(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Harvard College, Dana Farber Cancer Inst Inc filed Critical Harvard College
Application granted granted Critical
Publication of ATE360061T1 publication Critical patent/ATE360061T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT95907356T 1994-01-10 1995-01-09 Replikationsmangelhafte mutanten von herpesvirus ATE360061T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17910694A 1994-01-10 1994-01-10
US08/278,601 US7223411B1 (en) 1992-07-31 1994-07-21 Herpesvirus replication defective mutants

Publications (1)

Publication Number Publication Date
ATE360061T1 true ATE360061T1 (de) 2007-05-15

Family

ID=26874996

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95907356T ATE360061T1 (de) 1994-01-10 1995-01-09 Replikationsmangelhafte mutanten von herpesvirus

Country Status (7)

Country Link
US (1) US7223411B1 (de)
EP (1) EP0739414B1 (de)
JP (1) JPH09508788A (de)
AT (1) ATE360061T1 (de)
CA (1) CA2180551A1 (de)
DE (1) DE69535466T2 (de)
WO (1) WO1995018852A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020009462A1 (en) * 1992-07-31 2002-01-24 David M. Knipe Herpesvirus replication defective mutants
CA2234877A1 (en) * 1995-10-19 1997-04-24 St. Jude Children's Research Hospital Herpesvirus vectors and their uses
US20080226677A1 (en) * 2004-05-06 2008-09-18 Yasuko Mori Recombinant virus vector for gene transfer into lymphoid cells
US8257712B2 (en) * 2008-07-03 2012-09-04 Saint Louis University Virus-expressing host costimulation molecules
DK2516629T3 (en) 2009-12-21 2016-07-04 Brigham & Womens Hospital Inc Herpes simplex virus vaccines
WO2013177172A2 (en) 2012-05-21 2013-11-28 Sanofi Pasteur Limited Herpesvirus compositions and related methods
DK2943567T3 (en) 2013-01-08 2018-01-02 Genzyme Corp USE OF INOS INHIBITORS TO INCREASE VIRAL YIELD IN CULTURE
RU2531426C1 (ru) * 2013-06-24 2014-10-20 Государственное бюджетное учреждение "Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан" Способ лечения герпетического кератита
WO2015034807A2 (en) 2013-09-05 2015-03-12 Merck Sharp & Dohme Corp. Methods of immunization with varicella zoster virus antigen
WO2019152821A1 (en) 2018-02-05 2019-08-08 The Brigham And Women's Hospital, Inc. Recombinant herpes simplex virus-2 expressing glycoprotein b and d antigens

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769331A (en) 1981-09-16 1988-09-06 University Patents, Inc. Recombinant methods and materials
US4554159A (en) 1981-11-12 1985-11-19 Institute Merieux Vaccine and method of immunizing against herpes simplex virus (types 1 and 2)
US4859587A (en) 1984-06-04 1989-08-22 Institut Merieux Recombinant herpes simplex viruses, vaccines and methods
US5288641A (en) 1984-06-04 1994-02-22 Arch Development Corporation Herpes Simplex virus as a vector
AU6170486A (en) 1985-08-23 1987-02-26 Advanced Genetics Research Institute Defective viral vaccines
EP0277773A1 (de) 1987-01-30 1988-08-10 The Board Of Trustees Of The Leland Stanford Junior University Mischcytomegalovirus und Vakzin
CN1038306A (zh) 1988-03-21 1989-12-27 维吉恩公司 重组反转录病毒
AU631159B2 (en) 1988-11-14 1992-11-19 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Parvovirus capsids
JP3140757B2 (ja) 1989-02-06 2001-03-05 デイナ・フアーバー・キヤンサー・インステイテユート パッケージング欠陥ｈｉｖプロウイルス、細胞系及びその使用
FR2663228A2 (fr) 1989-09-29 1991-12-20 Agronomique Inst Nat Rech Composition immunisante contre la maladie de newcastle et procede de preparation.
CA2039921A1 (en) 1990-04-16 1991-10-17 Xandra O. Breakefield Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5328688A (en) 1990-09-10 1994-07-12 Arch Development Corporation Recombinant herpes simplex viruses vaccines and methods
US5837261A (en) * 1990-09-25 1998-11-17 Cantab Pharmaceuticals Research Limited Viral vaccines
AU658836B2 (en) 1990-09-25 1995-05-04 Xenova Research Limited Viral defective vaccine produced by transcomplementing cell line
US5665362A (en) 1990-09-25 1997-09-09 Cantab Pharmaceuticals Research Limited Viral vaccines
TW289731B (de) 1992-07-09 1996-11-01 Akzo Nv
JPH07500972A (ja) 1992-07-30 1995-02-02 アクゾ・ノベル・エヌ・ベー 非放出性ヘルペスウイルス生ワクチン
WO1994003207A1 (en) 1992-07-31 1994-02-17 President And Fellows Of Harvard College Herpesvirus vaccines
US5804413A (en) * 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
US5658724A (en) * 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
US5879934A (en) * 1992-07-31 1999-03-09 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
EP0689603A1 (de) 1993-03-19 1996-01-03 Cantab Pharmaceuticals Research Limited Defektiver mutanter nicht-retroviraler virus (2.b.hsv) zum impstoff

Also Published As

Publication number Publication date
CA2180551A1 (en) 1995-07-13
US7223411B1 (en) 2007-05-29
JPH09508788A (ja) 1997-09-09
WO1995018852A1 (en) 1995-07-13
DE69535466D1 (de) 2007-05-31
EP0739414B1 (de) 2007-04-18
EP0739414A1 (de) 1996-10-30
DE69535466T2 (de) 2008-01-03

Similar Documents

Publication Publication Date Title
DE69332501D1 (en) Herpesvirus impfstoffe
GB2217718B (en) Recombinant viruses,vaccines containing them and in vitro cell cultures thereof
ATE295895T1 (de) Genetischer impfstoff gegen den immunschwäche virus
DK157087A (da) Multivalent vaccine, isaer herpesvirusvaccine, dens anvendelse og deri indgaaende virus
CA2596274A1 (en) Recombinant mva virus, and the use thereof
JP2003502008A5 (de)
HUP0102478A2 (hu) A HCV-burokfehérjék által alkotott részecskék alkalmazása vakcinázásban
ES2176232T3 (es) Vacuna adecuada para ser utilizada en la prevencion y tratamiento de la infeccion por helicobacter.
EP0232798A3 (de) Pseudorabies-Virus-Mutanten, diese enthaltende Vakzine, Verfahren zu deren Herstellung sowie Methoden für deren Anwendung
GB2263480A (en) Viral defective vaccine produced by transcomplementing cell line
MX9700676A (es) Identificacion de la region de un gen citomegalovirus humano implicada en la desregulacion de la expresion de la cadena pesada del mhc de la clase i.
AU6489986A (en) Thymidine kinase deletion mutants of bovine herpersvirus-1, vaccines against infectious bovine rhinotracheitis containing same and methods for the production and use of same
DE69535466D1 (de) Replikationsmangelhafte mutanten von herpesvirus
ATE230798T1 (de) Rekombinanter herpes simplex gb-gd-impfstoff
MX26715A (es) Procedimiento para la preparacion de particulas antigenicas del virus de la hepatitis b en levaduras metilotroficas.
EP0541692A4 (en) Herpes simplex virus vp16 vaccines
FR2702152B1 (fr) Virus recombinants et leur utilisation en thérapie génique.
DK0956045T3 (da) Samlingsdeficient herpesvirusvaccine
AU2403188A (en) Infectious bovine rhinotracheitis virus mutants, vaccines containing same, methods for the production of same and methods for the use of same
DE69933875D1 (de) Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
Nesburn et al. Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection.
Kuklin et al. Modulation of mucosal and systemic immunity by enteric administration of nonreplicating herpes simplex virus expressing cytokines
GR3018820T3 (en) Use of il-4 to enhance immune response to immunogens in vaccines.
AU6383296A (en) Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
EP0668356A3 (de) Rekombinante, infektöse Rinder-Rhinotracheitis-Mutante, Methode zu deren Herstellung, und Vakzine dieselbige enthaltend

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties